Home
  • E-mailAgnete.Engelsen@uib.no
  • Phone+47 975 15 414
  • Visitor Address
    Jonas Lies vei 91
  • Postal Address
    Postboks 7804
    5020 Bergen

Immunforsvarets frontliner

A field report from Engelsen's research stay at the French Research Institute Gustave Roussy (Paris, France) in the norwegian journal Forskerforum explains how we aim to engage the immune system in the eradication of cancers. (Article by Kjerstin Gjengedal). 

On a quest to cure cancer

'The premature death from cancer of a close friend and colleague, made Agnete Engelsen even more determined to find a way to cure this devastating disease.'

The PhD interview/ cancer research. Article in the UiB Magazine by Jens Helleland Ådnanes. 

Read more about my opportunity to participate in the High-Impact Cancer Research (HICR): Cancer, Biology and Therapeutics Program at Harvard Medical School -a truly inspirational postgraduate medical education program!  

Translational Cancer Research requires a wide range of standaard and advanced methodologies. Read more about the excitement and international participation at the first fully web-based version of CCBIO 905 Methods in Cancer Biomarker Research. This course is part of The CCBIO Research School for Cancer Studies.

 

Great excitement at the Research fair in Bergen

Excited children and adults crowded the Research Fair when researchers at the Center for Cancer Biomarkers (CCBIO) displayed living cancer cells in the microscope and performed a play about the cancer cell Greedy Frieda.

Read more about the research communication in the newspaper Studvest

 

Online teaching/ courses: Read more about the first fully web-based version of CCBIO905: Methods in Cancer Biomarker Research

 

Academic responsibility: 

CCBIO901 Junior Scientist Symposium, PhD course, The CCBIO Research School for Cancer Studies, UiB (RSCS)

MED1BIOMED Biomedisinske Tema, Mandatory MD course, Department of Biomedicine, UiB 

CCBIO905 Methods in Cancer Biomarker Research, PhD course, The CCBIO Research School for Cancer Studies, UiB (RSCS)

HUCEL 320 Cell culture and cellular techniques: Flow Cytometry, Master course, Department of Biomedicine, UiB

 

Individual lectures: 

BMED331 Tumor biology,  Master course, Department of Biomedicine, UiB 

MED1BIOMED Biomedisinske Tema, Mandatory MD course, Department of Biomedicine, UiB 

CCBIO905 Methods in Cancer Biomarker Research, PhD course, The CCBIO Research School for Cancer Studies, UiB (RSCS)

BZL 256 Embryology, Department of Zoology, UiB

MED1BAS, FARM 260/NUTR, ODONT, Histology Mandatory preclinical MD lab courses, Department of Biomedicine, UiB

 

 

Academic article
  • Show author(s) 2021. Induction of alveolar and bronchiolar phenotypes in human lung organoids. Physiological Reports.
  • Show author(s) 2020. AXL is a driver of stemness in normal mammary gland and breast cancer. iScience. 1-40.
  • Show author(s) 2020. AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology. 973-999.
  • Show author(s) 2019. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
  • Show author(s) 2019. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer. 545-555.
  • Show author(s) 2019. AXL targeting overcomes human lung cancer cell resistance to NK- And CTL-mediated cytotoxicity. Cancer immunology research. 1789-1802.
  • Show author(s) 2018. Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance. Frontiers in Cell and Developmental Biology.
  • Show author(s) 2018. Cancer Immunotherapy 2017 (Paris, France). Progress and challenges. Bulletin du Cancer. 537-541.
  • Show author(s) 2018. A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 57-70.
  • Show author(s) 2017. Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. PLOS ONE. 1-19.
  • Show author(s) 2014. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells . Cancer Medicine. 812-824.
  • Show author(s) 2014. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. Journal of Immunology. 6192-6206.
  • Show author(s) 2011. Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma. PLOS ONE. 14 pages.
  • Show author(s) 2011. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathologica. 495-510.
  • Show author(s) 2010. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Research. 4274-4279.
  • Show author(s) 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • Show author(s) 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • Show author(s) 2008. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. International Journal of Cancer. 761-768.
  • Show author(s) 2008. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. The FASEB Journal. 3120-3128.
  • Show author(s) 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
Reader opinion piece
  • Show author(s) 2010. Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track - Letter. Cancer Research. 6393-6396.
Masters thesis
  • Show author(s) 2021. Human organotypic airway and lung organoids for the study of SARS-CoV-2 infectivity and cytopathology.
  • Show author(s) 2021. Development and Characterization of an ex vivo Organotypic Non-Small Cell Lung Cancer Model to Study the Effect of Elevated Oxygen Treatment.
  • Show author(s) 2019. The Role of Axl in Cancer and Stem Cell Plasticity: in vivo Lineage Tracing and Imaging Mass Cytometry Analysis.
Doctoral dissertation
  • Show author(s) 2013. Intratumoural Heterogeneity of Glioblastoma. Implications of Immature Phenotypes on Tumour Growth and Resistance to Treatment.
Academic chapter/article/Conference paper
  • Show author(s) 2020. Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. 22 pages.
  • Show author(s) 2017. The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. 28 pages.
Abstract
  • Show author(s) 2010. NG2 PROMOTES RESISTANCE TO IONIZING RADIATION BY ELEVATED PEROXIREDOXIN-1 AND DNA DAMAGE RESPONSE IN GLIOBLASTOMA MULTIFORME. Neuro-Oncology. 8-8.
  • Show author(s) 2009. Targeting the tumor stroma: a novel therapeutic strategy based on separate analysis of the malignant and stromal cell compartments in brain tumors. Neuro-Oncology. 221-222.
  • Show author(s) 2009. CD133-NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS DISPLAY TUMORIGENICITY IN VIVO. Neuro-Oncology. 917-917.
  • Show author(s) 2008. CD133-NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS DISPLAY TUMORGENICITY IN VIVO. Neuro-Oncology. 778-778.
Academic literature review
  • Show author(s) 2021. Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival. Cancers.
  • Show author(s) 2020. Hypoxia-driven intratumor heterogeneity and immune evasion. Cancer Letters. 1-10.
  • Show author(s) 2020. Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. Cancer Drug Resistance. 22 pages.
  • Show author(s) 2017. Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm. 53-66.

More information in national current research information system (CRIStin)

Research groups

Twitter